TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05951491

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Shoulder Exoskeleton
Description: The wearable shoulder exoskeleton prototype is under development at the University of Idaho to provide gravity support to the shoulder. Subjects will use the device at home for a period of 5-7 days for at least 2 hours per day.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Hand Exoskeleton
Description: The wearable hand exoskeleton prototype is under development at the University of Idaho to provide hand-opening support. Subjects will use the device at home for a period of 5-7 days for at least 2 hours per day.
Study: NCT05970107

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary Lymph Node Dissection
Description: ALND happens after cancer cells are found during a sentinel lymph node biopsy.~ALND can remove lymph nodes located above, below or directly underneath a muscle that runs along the side of the upper chest.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary Lymph Node Dissection
Description: ALND happens after cancer cells are found during a sentinel lymph node biopsy.~ALND can remove lymph nodes located above, below or directly underneath a muscle that runs along the side of the upper chest.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary Reverse Mapping
Description: Axillary reverse mapping (ARM) is a technique where blue dye is injected into the upper arm at surgery, allowing direct visualization of arm lymphatics and nodes during ALND

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary Reverse Mapping
Description: Axillary reverse mapping (ARM) is a technique where blue dye is injected into the upper arm at surgery, allowing direct visualization of arm lymphatics and nodes during ALND

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphaticovenous Bypass
Description: Lymphaticovenous bypass/anastomosis (LVB/LVA) involves supramicrosurgery in which the blocked lymphatic vessel of an affected limb is connected to a nearby vein with the aid of ultra-fine instruments and a powerful operating microscope.
Study: NCT06445517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISM8207
Description: Pharmaceutical formulation: Capsules Mode of Administration: Oral
Study: NCT04912024

Intervention type: DEVICE
Intervention: Intermittent Renal Replacement Therapy using the Tablo Hemodialysis System
Description: Intermittent renal replacement therapy using the Tablo Hemodialysis System in the acute setting for participants with AKI or ESKD

Intervention type: DEVICE
Intervention: Intermittent Renal Replacement Therapy using Conventional Hemodialysis Systems
Description: Intermittent renal replacement therapy using Conventional Hemodialysis Systems in the acute setting for participants with AKI or ESKD
Study: NCT04921358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: administered orally
Study: NCT05107362

Intervention type: DIAGNOSTIC_TEST
Intervention: untrained lay user performs investigational diagnostic test
Description: Untrained lay users (parents/guardians of pediatric subjects or friends/family members of adult subjects) collect throat swab specimens and perform the investigational diagnostic test.
Study: NCT05138380

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foot orthoses
Description: Manufacturer: Foot Science International.~Material: High grade thermoformable closed-cell polyolefin foam (medium density)~Arch support: inbuilt.~Covering: fabric~Provided by: Study Practitioner: Registered physiotherapist \> 2 years musculoskeletal experience will be trained to prescribe the insert according to the prescription algorithm.~Where: Administered via telehealth~When and how much: Week 0 to 1: one telehealth session with study practitioner to fit one pair of pre-fabricated orthoses Week 1 to 2: Follow-up session for questions if required~Tailoring: Orthoses are fit to comfort. Lengths (S, S, M, L, XL, XXL) (dependent on participant's shoe size). Hardness = Medium density. Modifications: can be cut to size to assist in fit using the shoes original sock liner as a guide, by participants using standard scissors. Heat molding: optional.~Adherence: Adherence recorded with diary/ log book (insert wear time)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Flat shoe insert
Description: Manufacturer: Foot Science International.~Material: High grade thermoformable closed-cell polyolefin foam (medium density)~Arch support: no.~Covering: fabric~Provided by: Study Practitioner: Registered physiotherapist \> 2 years musculoskeletal experience will be trained to prescribe the insert according to the prescription algorithm.~Where: Administered via telehealth~When and how much: Week 0 to 1: one telehealth session with study practitioner to fit one pair of pre-fabricated orthoses Week 1 to 2: Follow-up session for questions if required~Tailoring: Fit to comfort. Lengths (S, S, M, L, XL, XXL) (dependent on participant's shoe size). Hardness = Medium density. Modifications: can be cut to size to assist in fit using the shoes original sock liner as a guide, by participants using standard scissors. Heat molding: optional.~Adherence: Adherence recorded with diary/ log book (insert wear time)
Study: NCT04190056

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study: NCT05050643

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EBQI-IC
Description: Individual (ongoing) consultation (IC), often described as coaching or supervision, is endorsed by implementation experts as an effective implementation strategy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EBQI-IC
Description: Individual (ongoing) consultation (IC), often described as coaching or supervision, is endorsed by implementation experts as an effective implementation strategy
Study: NCT05343247

Intervention type: DIAGNOSTIC_TEST
Intervention: Cameriere method
Description: Cameriere et al. designed a quantitative approach through a formula based on sex and the ratio between length and apex opening measurements of each lower left tooth.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cameriere method
Description: Cameriere et al. designed a quantitative approach through a formula based on sex and the ratio between length and apex opening measurements of each lower left tooth.
Study: NCT05050643

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EBQI-LC
Description: A Learning Collaborative is a systematic approach to process improvement based on the Institute for Healthcare Improvement Breakthrough Series Collaborative model. During the Collaborative, organizations will test and implement system changes and measure their impact. They will share their experiences to accelerate learning and broader implementation of best practices.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EBQI-LC
Description: A Learning Collaborative is a systematic approach to process improvement based on the Institute for Healthcare Improvement Breakthrough Series Collaborative model. During the Collaborative, organizations will test and implement system changes and measure their impact. They will share their experiences to accelerate learning and broader implementation of best practices.
Study: NCT05343247

Intervention type: DIAGNOSTIC_TEST
Intervention: London Atlas method
Description: The London Atlas requires the user to assess the tooth development and eruption and then match it to one of the 31 pictures of age categories.

Intervention type: DIAGNOSTIC_TEST
Intervention: London Atlas method
Description: The London Atlas requires the user to assess the tooth development and eruption and then match it to one of the 31 pictures of age categories.
Study: NCT05732285

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CRT
Description: Participants that score 1-1.5 standard deviation (SD) below the norm for age and education on 2 cognitive domains will receive an intensive program, 2 CRT sessions per week for 4 weeks in addition to 1 CBT session per week for 8 weeks. Based on clinical experience, those with more severe cognitive deficits require more time to achieve their therapy goals, whereas those with mild deficits can tolerate a more intense therapy.~Participants that score 1.5-2 SD or more below the norm for age and education on 2 cognitive domains will receive 1 CRT and 1 CBT weekly sessions for 8 weeks. All the CRT sessions will be coupled with homework for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: Participants that score 1-1.5 standard deviation (SD) below the norm for age and education on 2 cognitive domains will receive an intensive program, 2 CRT sessions per week for 4 weeks in addition to 1 CBT session per week for 8 weeks. Based on clinical experience, those with more severe cognitive deficits require more time to achieve their therapy goals, whereas those with mild deficits can tolerate a more intense therapy.~Participants that score 1.5-2 SD or more below the norm for age and education on 2 cognitive domains will receive 1 CRT and 1 CBT weekly sessions for 8 weeks. All the CRT sessions will be coupled with homework for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modifiable lifestyle factors
Description: The therapy sessions are coupled with homework and requires some lifestyle modifications such lifestyle adjustments are using a calendar, a diary, maintaining a sleep schedule and exercise.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care Psychoeducation
Description: Participants will receive 15 minute psychoeducation session twice per week for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval).
Study: NCT03946761

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cancer goggle system
Description: -The cancer goggle system is being used as a non-significant risk device
Study: NCT05921370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg
Description: This prospective study will be conducted on patients prepared for Retrograde intrarenal surgery presented to Ain Shams University Hospital. Patients will be randomized with 1:1 ratio into 2 equal groups.~Group A (the study group): Patients will receive silodosin 8 mg one tablet per day for 7 days before their scheduled retrograde intrarenal surgery.~silodosin is an alpha blocker which act to dilate the ureter to facilitate access sheath placement

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This prospective study will be conducted on patients prepared for Retrograde intrarenal surgery presented to Ain Shams University Hospital. Patients will be randomized with 1:1 ratio into 2 equal groups.~Group A (the study group): Patients will receive silodosin 8 mg one tablet per day for 7 days before their scheduled retrograde intrarenal surgery.~Group B (the control group): Patients will receive Placebo for 7 days before their scheduled retrograde intrarenal surgery.
Study: NCT05641194

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Legacy Alerting System
Description: Description: Standard alerting system in place at the fire station.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention 2: EaseAlert Standalone
Description: Description: EaseAlert will activate and alert the subject of an emergency call without the legacy alerting system. EaseAlert (standalone) replaces the legacy alerting system.
Study: NCT04686097

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: treatment: puncture of coagulation
Description: ultrasound-guided puncture of coagulation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: treatment: sclerosing agent injected
Description: ultrasound-guided sclerosing agent injected
Study: NCT06461520

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maze Balance board
Description: Every child will have their balance evaluated using the SWOC tool, CTSIB, and Pediatric Balance Scale. Patients performed a range of proprioceptive exercises, such as static one-leg standing, board balancing, squatting, and 20 minutes of straight-line walking on a hard surface before moving to a foam surface. For 20 minutes each session, proprioceptive exercises were conducted with open eyes first, followed by closed ones. The training program for the maze balancing board will next take place. There will be seven phases to the maze balance board training; each stage will last for two days and there will be three sessions per day, each lasting an hour.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive training
Description: This group will get proprioceptive training. For a total of ten weeks, the intervention will be carried out three times a week for forty minutes each. Without maze-balance board training, the training schedule will consist of three sessions each week, lasting ten minutes each for preparatory, twenty minutes for proprioceptive, and ten minutes for restorative activities. Every meeting ended with a 10-minute cool-down and 10-minute warm-up to signify the quality of work.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proprioceptive training
Description: This group will get proprioceptive training. For a total of ten weeks, the intervention will be carried out three times a week for forty minutes each. Without maze-balance board training, the training schedule will consist of three sessions each week, lasting ten minutes each for preparatory, twenty minutes for proprioceptive, and ten minutes for restorative activities. Every meeting ended with a 10-minute cool-down and 10-minute warm-up to signify the quality of work.
Study: NCT06189092

Intervention type: DRUG
Intervention: Bleomycin
Description: Using electroporation to infuse bleomycin in the lesion
Study: NCT06566274

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: thumbtack needle
Description: As a kind of intradermal needle, thumbtack needle (TTN) is a method of shallow puncture and long-term needle.After the TTN is attached into the acupoints, it will be reserved in the acupoints for 3 days. After 3 days of retention of TTN, the patient is instructed to go to the hospital, where the doctor removes the needle, disinfect the local skin of acupoints and conducts the next TTN treatment. A total of 5 treatments were applied for a duration of 15 days.
Study: NCT05563142

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: deploying vascular closure device versus manual compression
Description: patients will be randomized to either group 1 or group 2 in a 1:1 ratio:

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: deploying vascular closure device versus manual compression
Description: patients will be randomized to either group 1 or group 2 in a 1:1 ratio:
Study: NCT06566274

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham thumbtack needle
Description: The sham TTN used in the sham TTN group has no needle body and its appearance and shape are similar to the real TTN. But it does not produce a needle-like effect.~The acupoints of sham TN group are the same as those of TN group. The use of sham TN is the same as that of the TN group. After 3 days retention of sham TN, the patient will be instructed to go to the hospital, where the doctor remove the sham TN, and conduct the next treatment after local skin disinfection. A total of 5 treatments will be applied for a duration of 15 days.
Study: NCT05819411

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project iSTRIVE
Description: This intervention includes 6 face-to-face therapy sessions with a trained clinician to develop skills to counter internalized stigma and shame as barriers to HIV self-care. Both the intervention group and the active control group will also receive a mobile app-based iDOT intervention.
Study: NCT05197049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 1
Description: Guselkumab (Dose 1) will be administered by subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 1
Description: Guselkumab (Dose 1) will be administered by subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 2
Description: Guselkumab (Dose 2) will be administered by SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 3
Description: Guselkumab (Dose 3) will be administered by SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by SC injection.
Study: NCT05421078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obicetrapib
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obicetrapib
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obicetrapib
Description: tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No active ingredient
Study: NCT06451523

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alliance180 Program
Description: The Alliance180 Program promotes feelings of neuropsychological safety and trust in the context of a 3-day program, which includes the transformative equine experience.
Study: NCT04368702

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Viewray MRIdian® Linac
Description: MR-image guided radiation will be administered per disease site standards.
Study: NCT05819411

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: incentivized Directly Observed Therapy (iDOT)
Description: Both the intervention group and the active control group will receive a mobile app-based iDOT intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: incentivized Directly Observed Therapy (iDOT)
Description: Both the intervention group and the active control group will receive a mobile app-based iDOT intervention.
Study: NCT04368702

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Viewray MRIdian® Linac
Description: MR-image guided radiation will be administered per disease site standards.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Viewray MRIdian® Linac
Description: MR-image guided radiation will be administered per disease site standards.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Viewray MRIdian® Linac
Description: MR-image guided radiation will be administered per disease site standards.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Viewray MRIdian® Linac
Description: MR-image guided radiation will be administered per disease site standards.
Study: NCT05074433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: casirivimab+imdevimab
Description: Co-administered sequentially subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: casirivimab+imdevimab
Description: Co-administered sequentially subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: casirivimab+imdevimab
Description: Co-administered sequentially subcutaneous (SC)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT04909879

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVI-MSC
Description: COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Excipient solution
Study: NCT06537336

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: QoL
Description: QoL measurements were conducted using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires-Core30 (EORTC-QLQ-C30).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QoL
Description: QoL measurements were conducted using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires-Core30 (EORTC-QLQ-C30).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lung function
Description: lung function tests using spirometry

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lung function
Description: lung function tests using spirometry
Study: NCT06264765

Intervention type: OTHER
Group type: OTHER
Intervention: scalp block
Description: The scalp block will be performed by the anesthesiologist 10 minutes before the pin head holder application (PHHA). Supraorbital and supratrochlear nerves will be blocked bilaterally with 6 ml of 0.5% bupivacaine injected vertically into the skin above the eyebrow midline. Auriculotemporal nerves will be blocked bilaterally by injecting 4 ml of 0.5% bupivacaine 1.5 cm anterior to the ear at the tragus level. The needle will be inserted perpendicular to the skin and the fascia will be injected deeply and superficially while the needle is withdrawn. Postauricular branches of the greater auricular nerves will be blocked bilaterally with 2 ml of 0.5% bupivacaine injected 1 cm posterior to the ear, between the bone and skin, at the level of the tragus. The greater, lesser, and third occipital nerves run along the upper nuchal line approximately halfway between the occipital prominence and the mastoid prominence.

Intervention type: OTHER
Group type: OTHER
Intervention: Incisional infiltration
Description: Incisional infiltration: 20 ml of 0.5% bupivacaine will be infiltrated by the surgeon into the PHHA points and surgical incision areas 10 minutes before PHHA. Two
Study: NCT06271226

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure
Description: With acupressure, massage or pressure is applied to certain points on the body with fingers, hands or palms. The pressed points are the points on the skin that are sensitive to bioelectrical impulses and can easily transmit them.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo acupressure
Description: n the placebo group, the preparations and forms applied to the experimental group will be applied in the same way, but in accordance with the literature, an area 1.5 cm away from the acupressure point that has no connection with the acupressure point will be selected and the application will be made in the form of light touch

Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: During the study, pain and physiological parameters will be monitored and recorded twice a day (morning and evening) for 2 days, without any application (other than the routine treatment given by the physician).